4DMedical shares (ASX: 4DX) are leading the ASX 200 today, rising 8.82% to A$3.95 and extending gains to 22% over two trading sessions, as commercial momentum in the United States and reclaimed technical levels trigger a powerful rally in the medical imaging specialist.
The 4DX share price has decisively reclaimed its 200-day simple moving average at A$3.65 on the day, and pushed back above shorter-term resistance at the 50-day SMA (A$3.86) and 30-day SMA (A$3.88). The breakout marks a significant shift in sentiment for the stock, which had traded below these key technical levels for much of the past quarter.
Why Are 4DMedical Shares Higher?
Sentiment has been boosted following the deployment of 4DMedical’s flagship CT:VQ imaging solution at Mayo Clinic, consistently ranked as the number-one hospital in the United States. The deployment sits alongside implementations at five other leading U.S. Academic Medical Centers, signalling that adoption is broadening beyond isolated pilot programmes into systematic institutional rollout.
For a medical technology company, validation from institutions of Mayo Clinic’s calibre represents one of the strongest forms of real-world endorsement available, supporting the thesis that CT:VQ can become a new standard of care in pulmonary imaging rather than remaining a niche diagnostic tool.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The commercial traction is reflected in the company’s financial performance. In its most recent half-year update, 4DMedical reported revenue growth of approximately 265% year-on-year to A$2.9 million, with its SaaS-based products now deployed across 301 sites globally, up from 242 sites in the prior half. The 24% increase in active sites over six months demonstrates that the company is firmly in scale-up mode. Gross margins remain above 90%, underpinning the bull case that once fixed overheads are absorbed, incremental revenue should flow heavily to EBITDA and eventually free cash flow.
4DMedical’s recent inclusion in the S&P/ASX 200 has added another layer to the stock’s momentum. Index inclusion typically triggers buying from passive and benchmark-hugging funds, though the stock experienced some profit-taking immediately after the event as early buyers sold into the news. Despite that initial dip, the longer-term effect has been to attract structural, long-only capital and increase the stock’s visibility among institutional investors.
What Next?
The reclaim of the 200-day moving average is significant not merely as a technical event, but because it is occurring against a backdrop of tangible commercial progress. Markets are increasingly willing to underwrite the view that 4DMedical is transitioning from an early-stage story to a genuine growth company with institutional adoption, regulatory clearances in major markets, and a clear path to revenue scale.
There has also been a broader move back into healthcare and software names in recent sessions after a period of pressure.
The bull case rests on the thesis that CT:VQ can become a widely adopted imaging modality, leveraging SaaS economics to drive high incremental margins as site count and scan volumes grow. The Mayo Clinic deployment, combined with the broader AMC rollout and European expansion, supports this narrative. The Pro Medicus strategic investment adds further credibility, signalling interoperability with leading imaging ecosystems and potential for deeper commercial partnerships.
However, execution risk remains high. Despite explosive percentage growth rates, absolute revenue remains modest relative to the company’s market capitalisation, which has expanded significantly over recent years. Converting pilot programmes into multi-site commercial contracts, navigating complex reimbursement environments, and sustaining growth without further dilution are all challenges that lie ahead. Bears also point to the ongoing need for capital raises and option exercises, which have diluted shareholders over time, and argue that the business model is not yet self-sustaining.
From a technical perspective, the reclaim of the 200-day SMA and shorter-term moving averages suggests that the path of least resistance may be higher in the near term, particularly if short covering accelerates. However, the stock’s history of sharp reversals after euphoric runs means that traders are likely to remain vigilant for signs of exhaustion.
Bull Case:
- Mayo Clinic and top-tier AMC deployments validate CT:VQ as emerging standard of care
- Revenue growth of 265% year-on-year with 90%+ gross margins demonstrates operating leverage
- A$45 million cash balance and Pro Medicus backing fund multi-year expansion without dilution risk
- CE Mark unlocks European commercial rollout, materially expanding total addressable market
- Index inclusion and high short interest create technical tailwinds for further upside momentum
Bear Case:
- Absolute revenue remains modest relative to market cap, raising valuation and execution concerns
- Ongoing dilution from placements and option exercises erodes per-share value over time
- Complex reimbursement and regulatory environments across geographies pose scaling risks
- High retail and momentum participation increases vulnerability to sharp reversals after rallies
- Business model not yet self-sustaining, with potential for further capital raises if growth slows
